Cayman FLT3/CD135 Intracellular Domain (human, recombinant)

FMS-like tyrosine kinase 3 (FLT3), also known as CD135, is a transmembrane cytokine receptor and member of the class III receptor tyrosine kinase family.¹ It is composed of five extracellular immunoglobulin-like (Ig-like) domains, a transmembrane domain, an intracellular juxtamembrane domain, and two intracellular kinase domains. FLT3 is expressed in immature myeloid, lymphoid, and dendritic progenitor cells. Upon binding of FLT3 ligand, FLT3 forms a homodimer and the kinase domains are trans-phosphorylated, leading to activation of the RAS/MEK/ERK, PI3K, and STAT5A signaling pathways in a cell type-dependent manner.^1,2 It is involved in the growth, survival, and differentiation of hematopoietic cells. FLT3 is considered a protooncogene, and activating mutations in it are associated with shorter disease-free survival in patients with hematologic malignancies.^1,3 A mutation in FLT3 that results in an internal tandem duplication (ITD) of the juxtamembrane domain in FLT3 is found in approximately 20% of patients with acute myeloid leukemia (AML) and is associated with leukocytosis and poor prognosis.^3,4 Formulations containing inhibitors of FLT3 have been used in the treatment of AML but are associated with chemoresistance.² Cayman’s FLT3/CD135 Intracellular Domain (human, recombinant) protein can be used for enzyme activity assays.

WARNING This product is not for human or veterinary use.